We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Roivant Sciences Ltd | NASDAQ:ROIV | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.18 | -1.58% | 11.23 | 11.23 | 11.48 | 11.45 | 10.91 | 11.40 | 3,949,640 | 23:55:48 |
From May 2023 to May 2024
1504 ET -- Roche Holding and Pfizer are among the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Roche agreed to buy Telavant Holdings from Roivant Sciences and Pfizer, a deal that includes $7.1 billion upfront and a near-term milestone payment of $150 million. Telavant is developing a bowel-disease treatment. On Friday, Pfizer said the Food and Drug Administration approved Penbraya, a vaccine for meningococcal disease. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)
(END) Dow Jones Newswires
October 23, 2023 15:26 ET (19:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roivant Sciences Chart |
1 Month Roivant Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
